Radiopharm Theranostics RADX
NASDAQ RADX
$2.29 -0.21 (-8.40%)
At close: Aug 20, 2026 · 4:00 PM EDT

Radiopharm Theranostics Ltd (RADX) Receivables - Net (2023 - 2025)

Radiopharm Theranostics (RADX) posted quarterly Receivables - Net of $66605.4 for Q2 2025, up 923.55% year-over-year from $6507.3 in Q2 2024, and up 923.55% quarter-over-quarter from $6507.3 in Q2 2024.

Radiopharm Theranostics Ltd (RADX) Receivables - Net (2023 - 2025) Analysis & Trends

Radiopharm Theranostics (RADX) has reported Receivables - Net for 3 consecutive years, with $66605.4 the latest figure, recorded in Q2 2025.

  • In Q2 2025, Receivables - Net rose 923.55% year-over-year to $66605.4; the TTM figure through Jun 2025 stood at $66605.4 (up 923.55% YoY), while the FY2025 annual figure was $10.4 million, up 953.26% from the prior year.
  • Receivables - Net advanced to $66605.4 in Q2 2025 per RADX's latest filing, from $6507.3 in the prior quarter.
  • Across five years, Receivables - Net topped out at $4.5 million in Q2 2023 and bottomed at $6507.3 in Q2 2024.
  • Historically, Receivables - Net has averaged $1.5 million across 3 years, with a median of $66605.4 in 2025.
  • Annual changes were most pronounced in 2024 — Receivables - Net sank 99.85% — and 2025, when it surged 923.55%.
  • Radiopharm Theranostics' Receivables - Net stood at $4.5 million in 2023, then tumbled by 99.85% to $6507.3 in 2024, then soared by 923.55% to $66605.4 in 2025.
  • Business Quant data shows RADX's Receivables - Net at $66605.4 in Q2 2025, $6507.3 in Q2 2024, and $4.5 million in Q2 2023.

Peer Comparison

Historic Data

Download Data
DateValue
Jun 30, 2025 66,605.44
Jun 30, 2025 66,605.44
Jun 30, 2024 6,507.29
Jun 30, 2024 6,507.29
Jun 30, 2023 4.47 Mn
Jun 30, 2023 4.47 Mn